Localized Non-Resectable Adult Hepatocellular Carcinoma Clinical Trial
Official title:
Chemoembolization of Non-resectable Non-metastatic Hepatocellular Carcinoma Using Embolization Microspheres (DC Bead™) Loaded With Idarubicin (Zavedos®): Phase 1 Study
Chemoembolization is a recognized treatment strategy for hepatocellular carcinoma (HCC)
- classical chemoembolization consists in injecting an emulsion of an anticancer agent in
Lipiodol® via the hepatic artery
- doxorubicin, an anthracycline, is the most frequently used drug in lipiodol
chemoembolization (LCE)
- however, less than half of HCC respond favourably to classical lipiodol
chemoembolization (LCE) with doxorubicin/Lipiodol®
In this trial, we propose to introduce in clinical practice a strategy based on idarubicin
to achieve a more effective antitumor effect for the following reasons, recently pointed out
by our team:
- idarubicin is an anthracycline that penetrates tumour cells more quickly and is more
cytotoxic than doxorubicin on hepatocellular carcinoma cell lines
- idarubicin is injected in a solution of embolization microspheres of a diameter of
(300-500µm), which all the progressive and controlled release of the anticancer drug,
whereas the doxorubicin/Lipiodol® emulsion is unstable
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02072486 -
Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
|
N/A | |
| Completed |
NCT01910909 -
Stereotactic Body Radiotherapy for Unresectable Hepatocellular Carcinoma
|
N/A |